In what year did keytruda receive fda approval?

When did Keytruda receive FDA approval?

Keytruda received its first FDA approval in September 2014 for treating advanced melanoma.

How long has Keytruda been on the market?

Keytruda has been available since 2014, making it a 10-year-old drug in 2024.

What cancers has Keytruda been approved for?

Keytruda holds approvals for more than 20 different cancer types, including lung, head and neck, kidney, bladder, and liver cancers.

How does Keytruda compare with Opdivo?

Keytruda and Opdivo are both PD-1 inhibitors that block the checkpoint protein to help the immune system attack cancer. They cover similar cancer types but differ in dosing schedules and approved indications.

What is the current price of Keytruda?

Keytruda costs about $11,000 per dose every three weeks. The annual treatment cost can reach $180,000 without insurance coverage.

When does Keytruda's patent expire?

Keytruda's composition of matter patent expires in 2028. Some method-of-use patents extend to 2032.

Why are companies challenging this patent?

Several biosimilar makers have filed Paragraph IV challenges against Keytruda's patents, hoping to launch generic versions earlier than 2028.

Can biosimilars enter before patent expiry?

Biosimilars may enter the market as soon as 2028 if patent challenges succeed, but most analysts expect full market entry closer to 2032 when broader patents fall.

Who makes Keytruda?

Keytruda is manufactured by Merck & Co.